Bleeding Disorders Treatment Market Size and Forecast 2024-2033|AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc

Overview and Scope

Bleeding disorders are a group of diseases caused due to the inability of the blood to clot properly. Symptoms of bleeding disorders include extended bleeding after surgery, injury, menstruation, or trauma. The treatment is used to either stop or reduce the frequency of bleeding episodes.

Sizing and Forecast

The bleeding disorders treatment market size has grown strongly in recent years. It will grow from $15.37 billion in 2023 to $16.84 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increased patient awareness, access to healthcare, advancements in hemophilia therapies, global market expansion.

The bleeding disorders treatment market size is expected to see strong growth in the next few years. It will grow to $23.71 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to aging population, personalized medicine, patient advocacy and support, rise in disposable income, rise in healthcare expenditure. Major trends in the forecast period include personalized treatment plans, expansion of telehealth services, advanced clotting factor therapies, rna-based treatments, access to orphan drug designation.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

Segmentation & Regional Insights

The bleeding disorders treatment market covered in this report is segmented –

1) By Treatment: Desmopressin (DDAVP), Hormone Replacement Therapy, Contraceptives, Anti-Fibrinolytic or Clot-Stabilizing Drugs, Fibrin Sealants, Drugs Applied To Cuts, Pipeline Analysis

2) By Disease Type: Hemophilia A, Hemophilia B, Von willebrand disease, Liver disease, Other Disease Types

3) By End User: Hospitals, Clinics, Speciality Clinics, Research Institutes, Other End Users

North America was the largest region in the bleeding disorders treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7843&type=smp

Major Driver Impacting Market Growth

The increase in the number of diagnosed hemophilia patients is expected to propel the growth of the bleeding disorders treatment market going forward. Hemophilia is an inherited bleeding disorder where the blood does not clot properly. The treatment of Hemophilia entails replacement therapy, in which the missing or insufficient blood clotting factors are replaced with human plasma concentrates or recombinant (created from DNA) forms of clotting factors VIII or IX. For instance, in2021, according to the World Federation of Hemophilia, a Canada-based international, non-profit organization, there were almost 234,000 people confirmed to have hemophilia worldwide. . Therefore, the increasing number of diagnosed hemophilia patients is driving the growth of the bleeding disorders treatment market.

Key Industry Players

Major companies operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.

The bleeding disorders treatment market report table of contents includes:

1. Executive Summary

2. Bleeding Disorders Treatment Market Characteristics

3. Bleeding Disorders Treatment Market Trends And Strategies

4. Bleeding Disorders Treatment Market – Macro Economic Scenario

5. Global Bleeding Disorders Treatment Market Size and Growth

26. South America Bleeding Disorders Treatment Market

27. Brazil Bleeding Disorders Treatment Market

28. Middle East Bleeding Disorders Treatment Market

29. Africa Bleeding Disorders Treatment Market

30. Bleeding Disorders Treatment Market Competitive Landscape And Company Profiles

Top Major Players: